Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre
by
, , , , , , , and
Antonio De Leo
1,2,†,
Daniela Serban
2,†,
Thais Maloberti
1,2,
Viviana Sanza
1,
Sara Coluccelli
1,2,
Annalisa Altimari
1,
Elisa Gruppioni
1,
Federico Chiarucci
3,
Angelo Gianluca Corradini
4,
Andrea Repaci
5,
Alessandra Colapinto
5,
Margherita Nannini
2,6,
Maria A. Pantaleo
2,6,
Dario de Biase
1,7,‡ and
Giovanni Tallini
1,2,*,‡ 1
Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
2
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy
3
Anatomic Pathology, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy
4
Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
5
Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
6
Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
7
Department of Pharmacy and Biotechnology, University of Bologna, 40127 Bologna, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(4), 4057; https://doi.org/10.3390/ijms24044057
Submission received: 14 December 2022
/
Revised: 4 February 2023
/
Accepted: 13 February 2023
/
Published: 17 February 2023
(This article belongs to the Special Issue Advances in Metabolism, Immunology, Genetics in Thyroid Cancer and Thyroid Disease: From Bench to Therapy)
Abstract
:The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is potentially related to aggressive behavior and persistent disease. BRAF alterations other than the p.V600E are less common in thyroid carcinoma and represent an alternative mechanism of BRAF activation with unclear clinical significance. The study aims to describe the frequency and clinicopathologic characteristics of BRAF non-V600E mutations in a large cohort (1654 samples) of thyroid lesions characterized by next-generation sequencing. BRAF mutations have been found in 20.3% (337/1654) of thyroid nodules, including classic (p.V600E) mutation in 19.2% (317/1654) of samples and non-V600E variants in 1.1% of cases (19/1654). BRAF non-V600E alterations include 5 cases harboring p.K601E, 2 harboring p.V600K substitutions, 2 with a p.K601G variant, and 10 cases with other BRAF non-V600E alterations. BRAF non-V600E mutations have been reported in one case of follicular adenoma, three cases of conventional papillary thyroid carcinoma, eight cases of follicular variant of papillary carcinomas, one case of columnar cell variant papillary thyroid carcinoma, one case of oncocytic follicular carcinoma, and two bone metastasis of follicular thyroid carcinoma. We confirm that BRAF non-V600E mutations are uncommon and typically found in indolent follicular-patterned tumors. Indeed, we show that BRAF non-V600E mutations can be found in tumors with metastatic potential. However, in both aggressive cases, the BRAF mutations were concomitant with other molecular alterations, such as TERT promoter mutation.
1. Introduction
Diagnostic thyroidectomy is currently the recommended definitively procedure to exclude malignancy in patients with worrisome thyroid nodules. Molecular testing is commonly used to characterize tumors of follicular cell derivation: the BRAF p.V600E, RAS point mutations, and fusion oncogenes (e.g., RET/PTC fusion gene) are the most frequent molecular alterations [1,2,3,4,5]. BRAF gene codes for a protein belonging to a family of serine-threonine protein kinases that also includes ARAF and CRAF. RAF proteins play an important role in the MAP kinase signaling cascade, one of the pathways involved in cell proliferation and differentiation.
BRAF mutations are found in 60–80% of papillary thyroid carcinomas (PTC), and the most frequent alteration is the BRAF p.V600E. This mutation consists of a single nucleotide substitution involving the thymine in position 1799 (transversion, c.1799T > A). This mutation results in a valine to glutamate substitution at amino acid 600 (BRAF p.V600E) that mimics BRAF phosphorylation, causing constitutive activation of the protein. This activation leads to increased and uncontrolled cell proliferation necessary for tumor transformation and promotion. A previous study has demonstrated that BRAF mutation may be heterogeneously distributed in PTCs [6]. In PTCs, the BRAF p.V600E mutation has been associated with extrathyroidal extension, lymph nodal and distant metastases, higher stage, and risk of recurrence.
Even if BRAF p.V600E is the most common alteration in PTC, other less common BRAF non-V600E alterations are known, both in codons 599-600-601 or in other residues involved in DFG (Asp-Phe-Gly) motif (Residues 594–596) or activation loop (residues 596–601) [7,8]. Previous studies have demonstrated that mutations involved in codons 599–601 (e.g., p.V600E, p.K601E, and p.V600K) or codon 469 (e.g., p.G469V) may significantly influence BRAF activity [9,10,11], causing constitutive activation of the protein. On the contrary, substitutions present in other codons of BRAF genes do not seem to have the oncogenic potential [7,9]. According to their activity, BRAF mutations have been classified into three functional classes [9,12,13]: (i) class 1 BRAF mutations (BRAF p.V600), RAS independent, signal as monomers, and characterized by strong activity of BRAF kinase domain; (ii) class 2 BRAF alterations, RAS independent, signal as constitutive dimers, and with intermediate to high activity of BRAF kinase domain; (iii) class 3 BRAF alterations, RAS dependent, characterized by low or absent kinase activity.
The aim of the present study was to report the experience of the Bologna molecular pathology laboratory regarding the frequency of BRAF non-V600E alterations in a large clinical cohort of thyroid nodules.
2. Results
A total of 336 of the 1654 thyroid samples analyzed (20.3%) harbored a BRAF mutation (Table 1). Of 336 mutations, 317 (94.3%) were the canonical BRAF p.V600E variant, and the remaining 19 (5.7%) were BRAF non-V600E mutations (Table 1). One of the 19 non-V600E mutations was on exon 11, and the remnants were on exon 15. (Table 2).
The BRAF mutational status and clinicopathological features of the specimens harboring non-V600E mutation are reported in Table 2 and Table 3.
A total of 20 mutations were detected in 19 cases. In one case (case#1—Table 2), a BRAF p.V600E mutation was coexistent with a BRAF non-V600E variant (p.K601_W604del—Table 2). Of the 19 non-V600E mutations, 11 (57.9%) were single nucleotide variants (SNVs), and 8 (42.1%) were “indel” variants (Table 2). Nine of the non-V600E mutations were p.K601E (5 cases), p.V600K (2 cases), or p.K601G (2 cases), while the remaining 10 variants were all different between them (Table 2 and Table 3).
Follicular variant papillary thyroid carcinoma (FV-PTC) was the most common histological subtype harboring BRAF non-V600E mutations (8 of 19 cases, 42.1%). BRAF non-V600E mutations were also observed in one case of follicular adenoma (5.3%), three cases of conventional papillary thyroid carcinoma (15.8%), one case of columnar cell variant papillary thyroid carcinoma (5.3%), one case of oncocytic carcinoma (5.3%), and two bone metastases of follicular thyroid carcinoma (10.5%). Tumor capsule was present in five cases (Table 3 and Table 4). An extrathyroidal extension was observed in one classic papillary carcinoma (CL-PTC) (case #19—Table 4), while vascular invasion was detectable in three cases (Table 3 and Table 4). Cases with BRAF non-V600E mutations were mostly pT1 (10 of 13, 76.9%), including seven pT1a and three pT1b (Table 3). According to the AJCC (American Joint Committee on Cancer) prognostic stage, eleven cases were stage I, and one was stage II (Table 3 and Table 4). The vast majority of the samples harboring non-V600E were indolent thyroid lesions, but in two cases, distant (bone) metastases were detected at presentation (case #2, #3—Table 2 and Table 4, Figure 1).
3. Discussion
BRAF encodes the BRAF protein, which belongs to a family of serine-threonine protein kinases, including ARAF and CRAF. RAF proteins play an important role in the MAP kinase signaling cascade, one of the main pathways that regulate cell proliferation and differentiation. Mutant BRAF has been implicated in the pathogenesis of different types of cancer, including thyroid carcinoma, colorectal carcinoma, non-small cell lung carcinoma, ovarian carcinoma, gliomas, melanoma, and gastrointestinal stromal tumor (GIST) [14].
In this study, we investigated the prevalence and clinical significance of BRAF non-V600E variants in a large cohort of cases from a tertiary referral center. Next-generation sequencing allowed the detection of BRAF non-V600E mutations in 1.2% of 1654 thyroid nodules. BRAF non-V600E mutations are uncommon. They are typically found in indolent follicular-patterned tumors, and thus—in spite of being BRAF mutated forms—belong to the spectrum of thyroid tumors with RAS-like features (instead of belonging to the spectrum of BRAF-V600E-like tumors). In the TCGA cohort, of 240 mutated cases, 5 (2.1%) harbored non-V600E mutations. All of them were FV-PTC with p.K601E substitution or inframe deletions/insertion (cBioPortal—“Thyroid Carcinoma—TCGA”, Firehose Legacy).
BRAF p.K601E mutation represented the most common BRAF non-V600E alteration and, in agreement with other published case series, was only detected in follicular-patterned tumors (see Table 4) [15,16]. BRAF p.K601E has been reported in a few cases of follicular thyroid carcinoma [11,17,18], as well as in one case of NIFTP [19] and four cases of follicular adenoma [11,20,21,22]. Similar to previous reports, we found BRAF p.K601E in follicular variant PTC (four cases) as well as in one case of follicular adenoma. In our series, K601E-mutant FV-PTC showed no aggressive features, such as extrathyroidal extension, vascular invasion, or metastases, supporting the notion that BRAF p.K601E mutated thyroid nodules are typically indolent, in contrast to BRAF p.V600E mutated carcinomas [23,24]. In addition to BRAF p.K601E, we identified other non-V600E mutations not only in follicular-patterned tumors (two FV-PTC and three FTC) but also in three classical PTCs and in one CCV-PTC. Interestingly, a recent study reported that CCV-PTC appears to harbor a higher incidence of non-V600E variants [25].
Among BRAF non-V600E and non-K601E mutations, BRAF p.T599del was detected in one FV-PTC. This mutation has previously been reported in an adenomatous goiter [18,26]. BRAF p.K601_W604del was found in one of our FV-PTC cases. The mutation has previously been reported in papillary thyroid carcinoma [26,27]. BRAF p.T599_V600insEAT, detected in one classical PTC from our cohort, has never been previously reported in thyroid lesions but was identified in a single case of Langerhans cell histiocytosis [26,28]. We found one BRAF exon 11 mutation (p.G469S) in a case of FV-PTC. This mutation, too, had never been previously reported in thyroid lesions, but it was identified in hematopoietic and in solid tumors (e.g., melanomas, lung adenocarcinoma, and bile duct adenocarcinoma) [26].
The vast majority of the samples harboring BRAF non-V600E mutations were indolent thyroid lesions. However, we identified BRAF non-V600E mutations in two FTC patients with distant (bone) metastases at presentation. One FTC harbored BRAF p.A598_T599insILA and the other BRAF p.K601N. BRAF p.A598_T599insILA has never been previously reported. BRAF p.K601N has been reported in rare cases of FTC, thyroid lymphoma, lung carcinoma, colorectal carcinomas, and melanoma [26,29,30]. Intriguingly, the two cases with aggressive behavior harbored another mutation other than BRAF non-V600E: in one case, a pathogenic TERT promoter mutation was detected (case #2, Table 2); the other case harbored a 19q imbalance (case #3, Table 2) [30].
In conclusion, our results expand the spectrum of BRAF non-V600E mutations in thyroid nodules. We have confirmed that BRAF non-V600E mutations are uncommon and typically found in indolent follicular-patterned tumors. We report for the first time three BRAF non-V600E variants previously undetected in thyroid tumors, including one concomitant with TERT mutation and associated with distant metastasis. Indeed, we show that BRAF non-V600E mutations can be found in tumors with metastatic potential if associated with other molecular alterations. Thus, BRAF non-V600E mutated tumors should be thoroughly investigated, looking for thyroid tumor progression-related molecular changes such as TERT promoter mutation.
4. Materials and Methods
4.1. Case Selection
Data about 1654 thyroid nodules subjected to BRAF mutation analysis from January 2011 until June 2019 were collected from the database of the solid tumor molecular athology laboratory (Bologna, Italy). Analyses were performed starting from fine-needle aspiration specimens (“Direct fine needle aspiration cytology specimen” or “Stained cytological smear”) or surgical material (formalin-fixed and paraffin-embedded tissue—FFPE). The cytopathological and histopathological review was performed by two expert pathologists (GT, ADL) according to World Health Organization classification of thyroid malignancy [31].
4.2. DNA Extraction and BRAF Analysis
DNA from FFPE specimens was extracted starting from 2 to 4 serial 10 µm-thick sections using the QuickExtract FFPE DNA extraction kit (LGC Biosearch Technologies, Berlin, Germany), scraping the area of interest, according to the selection performed by a pathologist on final hematoxylin and eosin (E&H) slide. DNA was quantified using Qubit dsDNA BR assay kit (Thermo Fisher Scientific, Waltham, MA, USA). DNA from cytological specimens was extracted using the MasterPure DNA purification kit (LGC Biosearch Technologies, Berlin, Germany), according to the manufacturer’s instructions. Sequencing was performed using different types of NGS: 454 GS-Junior (Roche Diagnostics, Basel, Switzerland) [6], or multigene custom panel by MiSeq (Illumina Inc., San Diego, CA, USA) and Gene Studio S5 sequencers (Thermo Fisher Scientific, Waltham, MA, USA) [32]. Results were analyzed using the Amplicon variant analyzer tool (Roche, Basel, Switzerland), Illumina Variant Studio (Illumina Inc., San Diego, CA, USA), IonReporter tool (ThermoFisher Scientific, Waltham, MA, USA), and the Integrative Genomics Viewer v.2.3 (IGV) tool http://software.broadinstitute.org/software/igv/, accessed on 30 November 2022). ACMG classification for the mutations was retrieved using the Varsome Database (https://varsome.com/, accessed on 30 November 2022).
Author Contributions
Conceptualization, A.D.L., D.S., D.d.B. and G.T.; methodology, T.M., V.S., S.C., A.A. and E.G.; formal analysis, F.C., A.G.C. and A.R.; investigation, D.S., A.C., M.N. and M.A.P.; writing—original draft preparation, A.D.L., D.S. and D.d.B.; writing—review and editing, G.T.; supervision, G.T. All authors have read and agreed to the published version of the manuscript.
Funding
The work reported in this publication was funded by the Italian Ministry of Health, RC-2022-2773478.
Institutional Review Board Statement
All the experimental procedures were carried out in accordance with the general authorization to process personal data for scientific research purposes from “The Italian Data Protection Authority” (http://www.garanteprivacy.it/web/guest/home/docweb/-/docwebdisplay/export/2485392 (accessed on 29 January 2021)). All information regarding human material was managed using anonymous numerical codes, and all samples were handled in compliance with the Helsinki Declaration (https://www.wma.net/fr/news-post/en-matierede-transfert-des-taches-la-securite-des-patients-et-la-qualitedes-soins-devraient-etre-primordiales/ (accessed on 29 January 2021). The study did not affect the clinical management of the involved patients’ samples.
Informed Consent Statement
Written informed consent for mutational analysis was obtained from all patients. Information regarding the human material was managed using anonymous codes, and all samples were handled in compliance with the Helsinki Declaration.
Data Availability Statement
All data is contained within the article.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Acquaviva, G.; Visani, M.; Repaci, A.; Rhoden, K.J.; de Biase, D.; Pession, A.; Giovanni, T. Molecular pathology of thyroid tumours of follicular cells: A review of genetic alterations and their clinicopathological relevance. Histopathology 2018, 72, 6–31. [Google Scholar] [CrossRef]
- Cibas, E.S.; Ali, S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017, 27, 1341–1346. [Google Scholar] [CrossRef] [Green Version]
- Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef] [Green Version]
- Luster, M.; Aktolun, C.; Amendoeira, I.; Barczynski, M.; Bible, K.C.; Duntas, L.H.; Elisei, R.; Handkiewicz-Junak, D.; Hoffmann, M.; Jarzab, B.; et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid 2019, 29, 7–26. [Google Scholar] [CrossRef] [PubMed]
- Rhoden, K.J.; Johnson, C.; Brandao, G.; Howe, J.G.; Smith, B.R.; Tallini, G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab. Investig. 2004, 84, 1557–1570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Biase, D.; Cesari, V.; Visani, M.; Casadei, G.P.; Cremonini, N.; Gandolfi, G.; Sancisi, V.; Ragazzi, M.; Pession, A.; Ciarrocchi, A.; et al. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2014, 99, E1530–E1538. [Google Scholar] [CrossRef] [Green Version]
- Acquaviva, G.; de Biase, D.; Diquigiovanni, C.; Argento, C.M.; De Leo, A.; Bonora, E.; Rhoden, K.J.; Pession, A.; Tallini, G. BRAF Exon 15 Mutations in Papillary Carcinoma and Adjacent Thyroid Parenchyma: A Search for the Early Molecular Events Associated with Tumor Development. Cancers 2020, 12, 430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torregrossa, L.; Viola, D.; Sensi, E.; Giordano, M.; Piaggi, P.; Romei, C.; Materazzi, G.; Miccoli, P.; Elisei, R.; Basolo, F. Papillary Thyroid Carcinoma with Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. J. Clin. Endocrinol. Metab. 2016, 101, 4413–4420. [Google Scholar] [CrossRef] [Green Version]
- Yao, Z.; Yaeger, R.; Rodrik-Outmezguine, V.S.; Tao, A.; Torres, N.M.; Chang, M.T.; Drosten, M.; Zhao, H.; Cecchi, F.; Hembrough, T.; et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017, 548, 234–238. [Google Scholar] [CrossRef] [Green Version]
- Pakneshan, S.; Salajegheh, A.; Smith, R.A.; Lam, A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45, 346–356. [Google Scholar] [CrossRef]
- Afkhami, M.; Karunamurthy, A.; Chiosea, S.; Nikiforova, M.N.; Seethala, R.; Nikiforov, Y.E.; Coyne, C. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. Thyroid 2016, 26, 242–247. [Google Scholar] [CrossRef]
- Comito, F.; Aprile, M.; Pagani, R.; Siepe, G.; Sperandi, F.; Gruppioni, E.; Altimari, A.; De Biase, D.; Melotti, B. Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: A single-institution experience. Melanoma Res. 2022, 32, 477–484. [Google Scholar] [CrossRef] [PubMed]
- Di Federico, A.; De Giglio, A.; Gelsomino, F.; De Biase, D.; Giunchi, F.; Palladini, A.; Sperandi, F.; Melotti, B.; Ardizzoni, A. Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. Cancers 2022, 14, 3472. [Google Scholar] [CrossRef] [PubMed]
- Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trovisco, V.; Soares, P.; Preto, A.; de Castro, I.V.; Lima, J.; Castro, P.; Maximo, V.; Botelho, T.; Moreira, S.; Meireles, A.M.; et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005, 446, 589–595. [Google Scholar] [CrossRef] [PubMed]
- Trovisco, V.; Vieira de Castro, I.; Soares, P.; Maximo, V.; Silva, P.; Magalhaes, J.; Abrosimov, A.; Guiu, X.M.; Sobrinho-Simoes, M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 2004, 202, 247–251. [Google Scholar] [CrossRef]
- Pennelli, G.; Vianello, F.; Barollo, S.; Pezzani, R.; Merante Boschin, I.; Pelizzo, M.R.; Mantero, F.; Rugge, M.; Mian, C. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 2011, 21, 1393–1396. [Google Scholar] [CrossRef]
- Schulten, H.J.; Salama, S.; Al-Mansouri, Z.; Alotibi, R.; Al-Ghamdi, K.; Al-Hamour, O.A.; Sayadi, H.; Al-Aradati, H.; Al-Johari, A.; Huwait, E.; et al. BRAF mutations in thyroid tumors from an ethnically diverse group. Hered. Cancer Clin. Pract. 2012, 10, 10. [Google Scholar] [CrossRef] [Green Version]
- Nikiforov, Y.E.; Seethala, R.R.; Tallini, G.; Baloch, Z.W.; Basolo, F.; Thompson, L.D.; Barletta, J.A.; Wenig, B.M.; Al Ghuzlan, A.; Kakudo, K.; et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016, 2, 1023–1029. [Google Scholar] [CrossRef] [Green Version]
- Lima, J.; Trovisco, V.; Soares, P.; Maximo, V.; Magalhaes, J.; Salvatore, G.; Santoro, M.; Bogdanova, T.; Tronko, M.; Abrosimov, A.; et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J. Clin. Endocrinol. Metab. 2004, 89, 4267–4271. [Google Scholar] [CrossRef] [Green Version]
- Macerola, E.; Torregrossa, L.; Ugolini, C.; Bakkar, S.; Vitti, P.; Fadda, G.; Basolo, F. BRAF(K601E) Mutation in a Follicular Thyroid Adenoma: A Case Report. Int. J. Surg. Pathol. 2017, 25, 348–351. [Google Scholar] [CrossRef] [PubMed]
- Soares, P.; Trovisco, V.; Rocha, A.S.; Lima, J.; Castro, P.; Preto, A.; Maximo, V.; Botelho, T.; Seruca, R.; Sobrinho-Simoes, M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22, 4578–4580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tallini, G.; De Leo, A.; Repaci, A.; de Biase, D.; Bacchi Reggiani, M.L.; Di Nanni, D.; Ambrosi, F.; Di Gioia, C.; Grani, G.; Rhoden, K.J.; et al. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. Cancers 2020, 12, 246. [Google Scholar] [CrossRef] [Green Version]
- Tallini, G.; de Biase, D.; Durante, C.; Acquaviva, G.; Bisceglia, M.; Bruno, R.; Bacchi Reggiani, M.L.; Casadei, G.P.; Costante, G.; Cremonini, N.; et al. BRAF V600E and risk stratification of thyroid microcarcinoma: A multicenter pathological and clinical study. Mod. Pathol. 2015, 28, 1343–1359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Janovitz, T.; Williamson, D.F.K.; Wong, K.S.; Dong, F.; Barletta, J.A. Genomic Profile of Columnar Cell Variant of Papillary Thyroid Carcinoma. Histopathology 2021, 79, 491–498. [Google Scholar] [CrossRef]
- Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis, H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2019, 47, D941–D947. [Google Scholar] [CrossRef] [Green Version]
- Cho, U.; Oh, W.J.; Bae, J.S.; Lee, S.; Lee, Y.S.; Park, G.S.; Lee, Y.S.; Jung, C.K. Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. J. Korean Med. Sci. 2014, 29, 1054–1060. [Google Scholar] [CrossRef] [Green Version]
- Brown, N.A.; Furtado, L.V.; Betz, B.L.; Kiel, M.J.; Weigelin, H.C.; Lim, M.S.; Elenitoba-Johnson, K.S. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014, 124, 1655–1658. [Google Scholar] [CrossRef] [Green Version]
- Aggarwal, N.; Swerdlow, S.H.; Kelly, L.M.; Ogilvie, J.B.; Nikiforova, M.N.; Sathanoori, M.; Nikiforov, Y.E. Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Mod. Pathol. 2012, 25, 1203–1211. [Google Scholar] [CrossRef] [Green Version]
- Repaci, A.; Salituro, N.; Vicennati, V.; Monari, F.; Cavicchi, O.; de Biase, D.; Ciarrocchi, A.; Acquaviva, G.; De Leo, A.; Gruppioni, E.; et al. Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter. Endocr. Pathol. 2021, 33, 519–524. [Google Scholar] [CrossRef]
- Lloyd, R.V.; Osamura, R.Y.; Klöppel, G.; Rosai, J. World Health Organization Classification of Tumours of Endocrine Organs, 4th ed.; WHO/IARC: Lyon, France, 2017.
- De Biase, D.; Acquaviva, G.; Visani, M.; Sanza, V.; Argento, C.M.; De Leo, A.; Maloberti, T.; Pession, A.; Tallini, G. Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel. Diagnostics 2020, 10, 250. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Follicular thyroid carcinoma metastatic to bone (sacrum), case 3 Table 1, harboring BRAF p.K601N. The tumor is follicular patterned, well-differentiated, and lacks the nuclear atypia of papillary carcinoma, mitotic activity, and tumor necrosis. Magnification: 100×.
Figure 1.
Follicular thyroid carcinoma metastatic to bone (sacrum), case 3 Table 1, harboring BRAF p.K601N. The tumor is follicular patterned, well-differentiated, and lacks the nuclear atypia of papillary carcinoma, mitotic activity, and tumor necrosis. Magnification: 100×.
Table 1.
BRAF results in the cohort analyzed.
| BRAF-Mutation | Number of Cases | Frequency (%) |
|---|---|---|
| p.V600E | 317 | 19.2 |
| Non-V600E | 19 | 1.1 |
| WT | 1230 | 74.4 |
| NA | 88 | 5.3 |
| TOTAL | 1654 | 100 |
WT, Wild-Type; NA, not assessable due to low quality/quantity DNA.
Table 2.
Cases harboring BRAF non-V600E Mutations.
| # | Age | Sex | Site | Starting Material | Cytopathologycal Report | Histopathological Report | BRAF-Mutation | ACMG Classification | BRAF Class | Other Alterations |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 64 | M | Thy | Cytological smear + FFPE | Thy3f | FV-PTC | p.V600E p.K601_W604del | P NA | 1 NA | / |
| 2 | 73 | M | Bone | FFPE | NA | FTC (metastasis) | p.A598_T599insILA | NA | NA | TERT c.-124C > T |
| 3 | 85 | F | Bone | FFPE | NA | FTC (metastasis) | p.K601N | P | 2 | Chr19 imbalance |
| 4 | 38 | M | Thy | FFPE | Thy3f | FV-PTC | p.K601E | P | 2 | / |
| 5 | 56 | F | Thy | Cytological smear | Thy3a | FV-PTC | p.K601E | P | 2 | / |
| 6 | 33 | F | Thy | Direct FNA | Thy4 | CL-PTC | p.V600_S605delinsDT | NA | NA | / |
| 7 | 68 | M | Thy | Cytological smear | Thy3a | FV-PTC | p.T599del | NA | NA | / |
| 8 | 77 | F | Thy | Direct FNA | Thy3a | FV-PTC | p.V600_K601insNTV | NA | NA | |
| 9 | 36 | F | Thy | Direct FNA | Thy3f | FA | p.K601E | P | 2 | / |
| 10 | 66 | F | Thy | FFPE + Direct FNA | Thy3a | FV-PTC | p.K601E | P | 2 | / |
| 11 | 58 | F | Thy | Direct FNA | Thy3a | NA * | p.K601G | P | 2 | / |
| 12 | 60 | M | Thy | Direct FNA | Thy3a | NA * | p.K601G | P | 2 | / |
| 13 | 40 | M | Thy | Cytological smear | Thy3f | FV-PTC | p.K601E | P | 2 | / |
| 14 | 53 | F | Thy | Cytological smear | Thy3a | NA * | p.V600delinsNM | NA | NA | / |
| 15 | 70 | F | Thy | Direct FNA | Thy3a | OC | p.V600K | P | 1 | / |
| 16 | 69 | F | Thy | Direct FNA | Thy4 | CL-PTC | p.V600K | P | 1 | / |
| 17 | 55 | F | Thy | FFPE | NA | CCV-PTC | p.V600_R603delfs | NA | NA | / |
| 18 | 43 | F | Thy | Direct FNA | Thy3a | CL-PTC | p.T599_V600insEAT | NA | NA | / |
| 19 | 58 | F | Thy | Direct FNA | Thy3a | FV-PTC | p.G469S | P | NA | / |
FFPE: Formalin-fixed and Paraffin-Embedded; FNA: Fine Needle Aspiration; Chr: chromosome; Thy: Thyroid; NA: Not Available; * Loss at follow-up; P: Pathogenic; PTC: Papillary Thyroid Carcinoma; CL: Classical; FV: Follicular Variant; CCV: Columnar Cell Variant FA: Follicular Adenoma; FTC: Follicular Thyroid Carcinoma; OC: Oncocytic Carcinoma; Note: FV-PTC includes invasive and noninvasive tumors (i.e., NIFTP: Noninvasive follicular thyroid neoplasm with papillary like nuclear features).
Table 3.
Summary of clinicopathological characteristics of the 19 cases harboring BRAF non-V600E alteration.
Table 3.
Summary of clinicopathological characteristics of the 19 cases harboring BRAF non-V600E alteration.
| Clinicopathologic Characteristics | n (%) |
|---|---|
| Age | |
| median (range) | 59.6 (33–80) |
| Sex (n = 19) | |
| Female | 14 (73.7%) |
| Male | 5 (26.3%) |
| Size (mm) | |
| median (range) | 14 (1–80) |
| Non-V600E BRAF Alterations (n = 19) | |
| p.K601E | 5 (26%) |
| p.V600K | 2 (10.5%) |
| p.K601G | 2 (10.5%) |
| Other BRAF non-V600E | 10 (53%) |
| Histology (n = 19) | |
| Follicular adenoma | 1 (5.3%) |
| CL-PTC | 3 (15.8%) |
| FV-PTC | 8 (42.1%) |
| CCV-PTC | 1 (5.3%) |
| FTC (metastasis) | 2 (10.5%) |
| OC | 1 (5.3%) |
| NA | 3 (15.8%) |
| Tumor capsule (n= 13) | |
| Yes | 5 (38.4%) |
| No | 8 (61.5%) |
| Extrathyroidal extension (n= 13) | |
| Yes | 1 (7.7%) |
| No | 12 (92.3%) |
| Vascular invasion (n= 13) | |
| Yes | 3 (23.1%) |
| No | 10 (76.9%) |
| pT (n= 13) | |
| pT1a | 6 (46.1%) |
| pT1b | 4 (30.8%) |
| pT2 | 2 (15.4%) |
| pT3 | 1 (7.7%) |
| AJCC stages (n= 15) | |
| I | 12 (80%) |
| II | 1 (6.6%) |
| IVB | 2 (13.3%) |
| Metastasis (n = 15) | |
| Present | 2 (13.3%) |
| Absent | 13 (86.7%) |
NA: Not Available; PTC: Papillary Thyroid Carcinoma; CL: Classical; FV: Follicular Variant; CCV: Columnar Cell Variant FA: Follicular Adenoma; FTC: Follicular Thyroid Carcinoma; OC: Oncocytic Carcinoma; Note: FV-PTC includes invasive and noninvasive tumors (i.e., NIFTP: Noninvasive follicular thyroid neoplasm with papillary like nuclear features).
Table 4.
Description of the clinicopathological characteristics of the 19 cases harboring BRAF non-V600E alterations.
Table 4.
Description of the clinicopathological characteristics of the 19 cases harboring BRAF non-V600E alterations.
| Case | Histological Type | Size (mm) | Stage | Vascular Invasion | Tumor Capsule | Extrathyroidal Extension | Necrosis | AJCC Prognostic Stage | BRAF |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FV-PTC | 23 | II | Yes | Yes | No | No | I | p.V600E p.K601_W604del |
| 2 | FTC (metastasis) | NA | NA | NA | NA | NA | NA | IVB | p.A598_T599insILA |
| 3 | FTC (metastasis) | NA | NA | NA | NA | NA | NA | IVB | p.K601N |
| 4 | FV-PTC | 9 | Ia | No | No | No | No | I | p.K601E |
| 5 | FV-PTC | 2 | Ia | No | No | No | No | I | p.K601E |
| 6 | CL-PTC | 10 | Ia | No | No | No | No | I | p.V600_S605delinsDT |
| 7 | FV-PTC | 15 | Ib | NA | NA | NA | NA | I | p.T599del |
| 8 | FV-PTC | 9 | Ia | No | No | No | No | I | p.V600_K601insTV |
| 9 | FA | 35 | NA | NA | NA | NA | NA | NA | p.K601E |
| 10 | FV-PTC | 10 | Ia | No | No | No | No | I | p.K601E |
| 11 | NA * | 9.6 | NA | NA | NA | NA | NA | NA | p.K601G |
| 12 | NA * | 15 | NA | NA | NA | NA | NA | NA | p.K601G |
| 13 | FV-PTC | 4 | Ia | No | No | No | No | I | p.K601E |
| 14 | NA * | 13 | NA | NA | NA | NA | NA | NA | p.V600delinsNM |
| 15 | OC | 16 | Ib | No | Yes | No | No | I | p.V600K |
| 16 | CL-PTC | 15 | Ib | No | No | No | No | I | p.V600K |
| 17 | CCV-PTC | 45 | III | Yes | Yes | No | Yes | II | p.V600fs |
| 18 | CL-PTC | 16 | Ib | Yes | Yes | Yes | No | I | p.T599_V600insEIAT |
| 19 | FV-PTC | 32 | II | No | Yes | No | No | I | p.G469S |
NA: Not Available; * Loss at follow-up; PTC: Papillary Thyroid Carcinoma; CL: Classical; FV: Follicular Variant; CCV: Columnar Cell Variant FA: Follicular Adenoma; FTC: Follicular Thyroid Carcinoma; OC: Oncocytic Carcinoma; Note: FV-PTC includes invasive and noninvasive tumors (i.e., NIFTP: Noninvasive follicular thyroid neoplasm with papillary like nuclear features).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
De Leo, A.; Serban, D.; Maloberti, T.; Sanza, V.; Coluccelli, S.; Altimari, A.; Gruppioni, E.; Chiarucci, F.; Corradini, A.G.; Repaci, A.; et al. Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre. Int. J. Mol. Sci. 2023, 24, 4057. https://doi.org/10.3390/ijms24044057
AMA Style
De Leo A, Serban D, Maloberti T, Sanza V, Coluccelli S, Altimari A, Gruppioni E, Chiarucci F, Corradini AG, Repaci A, et al. Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre. International Journal of Molecular Sciences. 2023; 24(4):4057. https://doi.org/10.3390/ijms24044057
Chicago/Turabian StyleDe Leo, Antonio, Daniela Serban, Thais Maloberti, Viviana Sanza, Sara Coluccelli, Annalisa Altimari, Elisa Gruppioni, Federico Chiarucci, Angelo Gianluca Corradini, Andrea Repaci, and et al. 2023. "Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre" International Journal of Molecular Sciences 24, no. 4: 4057. https://doi.org/10.3390/ijms24044057
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
